REGN
PHARMACEUTICAL PREPARATIONSRegeneron Pharmaceuticals, Inc. - Common Stock (REGN) [ST]
www.regeneron.com ↗▼ 0.80%
prev close
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Congressional Trades
14
All tracked trades
Members Trading
7
Unique members
Net Activity
-6
4 buys · 10 sells
Members Who Traded This Stock
14 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-11-18 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Buy | $1,001 - $15,000 | 219d ago | — | |
| 2025-04-08 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Sell | $1,001 - $15,000 | 440d ago | — | |
| 2025-04-07 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Sell | $15,001 - $50,000 | 440d ago | — | |
| 2025-02-12 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Sell | $1,001 - $15,000 | 497d ago | — | |
| 2025-01-24 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Sell | $1,001 - $15,000 | 527d ago | — | |
| 2025-01-15 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Buy | $1,001 - $15,000 | 525d ago | — | |
| 2024-11-19 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Sell | $1,001 - $15,000 | 594d ago | — | |
| 2024-11-13 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Sell | $15,001 - $50,000 | 587d ago | — | |
| 2024-10-15 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Sell | $1,001 - $15,000 | 615d ago | — | |
| 2023-11-13 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Sell | $1,001 - $15,000 | 957d ago | — | |
| 2023-08-21 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Buy | $1,001 - $15,000 | 1040d ago | — | |
| 2023-07-11 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Buy | $1,001 - $15,000 | 1066d ago | — | |
| 2023-06-22 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Sell | $1,001 - $15,000 | 1107d ago | — | |
| 2023-03-06 | REGNRegeneron Pharmaceuticals, Inc. - Common Stock | Sell | $1,001 - $15,000 | 1189d ago | — |
2025-11-18
Gilbert Cisneros
REGN
Amount
$1,001 - $15,000
Filed
219d ago
2025-04-08
Rob Bresnahan
REGN
Amount
$1,001 - $15,000
Filed
440d ago
2025-04-07
Jefferson Shreve
REGN
Amount
$15,001 - $50,000
Filed
440d ago
2025-02-12
Julie Johnson
REGN
Amount
$1,001 - $15,000
Filed
497d ago
2025-01-24
Josh Gottheimer
REGN
Amount
$1,001 - $15,000
Filed
527d ago
2025-01-15
Julie Johnson
REGN
Amount
$1,001 - $15,000
Filed
525d ago
2024-11-19
Josh Gottheimer
REGN
Amount
$1,001 - $15,000
Filed
594d ago
2024-11-13
Jonathan Jackson
REGN
Amount
$15,001 - $50,000
Filed
587d ago
2024-10-15
Greg Landsman
REGN
Amount
$1,001 - $15,000
Filed
615d ago
2023-11-13
Josh Gottheimer
REGN
Amount
$1,001 - $15,000
Filed
957d ago
2023-08-21
Josh Gottheimer
REGN
Amount
$1,001 - $15,000
Filed
1040d ago
2023-07-11
Josh Gottheimer
REGN
Amount
$1,001 - $15,000
Filed
1066d ago
2023-06-22
Josh Gottheimer
REGN
Amount
$1,001 - $15,000
Filed
1107d ago
2023-03-06
Josh Gottheimer
REGN
Amount
$1,001 - $15,000
Filed
1189d ago
Recent News
Powered by Polygon.io
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Clinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 | Benchmark More Than 1,800 Biopharma Deals with Various Indexes
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider
Dupilumab Achieves Record $11.9 Billion in Global Sales Amidst Continued Growth
Trade Timeline
Congressional activity, newest first
Gilbert Cisneros
2025-11-18 · Purchase
$1,001 - $15,000
Rob Bresnahan
2025-04-08 · Sale
$1,001 - $15,000
Jefferson Shreve
2025-04-07 · Sale
$15,001 - $50,000
Julie Johnson
2025-02-12 · Sale
$1,001 - $15,000
Josh Gottheimer
2025-01-24 · Sale
$1,001 - $15,000
Julie Johnson
2025-01-15 · Purchase
$1,001 - $15,000
Josh Gottheimer
2024-11-19 · Sale
$1,001 - $15,000
Jonathan Jackson
2024-11-13 · Sale
$15,001 - $50,000
Greg Landsman
2024-10-15 · Sale
$1,001 - $15,000
Josh Gottheimer
2023-11-13 · Sale
$1,001 - $15,000
Josh Gottheimer
2023-08-21 · Purchase
$1,001 - $15,000
Josh Gottheimer
2023-07-11 · Purchase
$1,001 - $15,000
Josh Gottheimer
2023-06-22 · Sale
$1,001 - $15,000
Josh Gottheimer
2023-03-06 · Sale
$1,001 - $15,000